Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

2014580 citationsJournal Article

Authors

Good health and well-being

Published in: Ophthalmology

Volume 121, Issue 11, pp. 2181-2192

Field-Weighted Citation Impact: 51.60